Regulating Compounding in the GLP-1 Era: A Conversatio | Essential: The Pharmacy Compounding Podcast

Regulating Compounding in the GLP-1 Era: A Conversatio | Essential: The Pharmacy Compounding Podcast

From Pharmacy Podcast Network by Pharmacy Podcast Network

May 7, 2026 · 1h 3m · Episode 2503

About this episode

The episode features a discussion on the regulatory landscape of compounding in the context of GLP-1 and peptides with guest Al Carter.

This episode we look at a bunch of statements from the FDA and from HHS Secretary Robert F. Kennedy, Jr. And of course there are peptides to talk about these days. Does anyone really know what’s going on with those?Our deep dive is a special one: Our guest is Al Carter, the CEO of the National Association of Boards of Pharmacy, and he gives us a totally different perspective on the regulatory landscape at the level that affects pharmacists every day.Links from the podcast:The latest FDA statement on DTE: https://fllw.me/4sL6zXw The Coalition for Compounding Excellence’s first audit process guide (compounding records and quality control): https://fllw.me/3Oew1qr FDA Law Blog on the state of peptide compounding: https://fllw.me/4cpFF2C National Association of Boards of Pharmacy: https://nabp.pharmacy Join APC! https://a4pc.org/join

People in this episode

Guest: Al Carter

Topics covered

  • compounding
  • regulation
  • pharmacy
  • FDA
  • peptides

Keywords

  • compounding
  • FDA
  • HHS
  • peptides
  • pharmacy regulation

Mentioned in this episode

Organizations: FDA, HHS

Products: peptides

More episodes of Pharmacy Podcast Network

Explore listener stats, chart rankings, contacts and more on the Pharmacy Podcast Network podcast page.